Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AntriaBio appoints Barry Sherman to board

This article was originally published in Scrip

Executive Summary

AntriaBio, a biopharmaceutical company focused on developing treatments for diabetes and metabolic diseases, has named Dr Barry Sherman to its board of directors. Notably, Dr Sherman was the first chief medical officer of Genentech in the mid-1990s following his role directing Genentech's clinical research and medical affairs teams. He has also served as president and CEO of StemPar Sciences, president and CEO of Anergen Inc, a founder of Pain Therapeutics, and the executive vice-president and co-founder of BiPar Sciences.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel